A Careful Starting Point
Although this article’s title refers to men, this discussion focuses on testosterone therapy for women. The clinical context matters: treatment for men with diagnosed hypogonadism and masculinizing hormone therapy are distinct from testosterone use in women, and their evidence and goals should not be treated as interchangeable.
Women produce testosterone too, in smaller amounts than men. A decision about treatment should begin with the reason for symptoms, whether evidence supports testosterone for that specific concern, and the person’s preferences and health history. Fatigue, changes in mood, and reduced sexual interest can have many causes, so symptoms alone do not establish that testosterone is appropriate.
Testosterone is not a general wellness or anti-aging treatment. For women, evidence supports considering it only for particular clinical circumstances, not as a broad way to improve energy or vitality. A qualified clinician can discuss potential benefits, uncertainties, risks, and alternatives as part of an individualized decision. The American Family Physician review of testosterone therapy describes its limited use in women and the need for careful assessment.
When Testosterone May Be Considered
For women, testosterone therapy means clinician-prescribed testosterone at a carefully adjusted dose to address a specific health concern. It is not a general treatment to boost energy, improve mood, sharpen thinking, or prevent aging.
Current evidence supports considering testosterone primarily for postmenopausal women with hypoactive sexual desire disorder (HSDD). HSDD involves a persistent reduction in sexual desire that causes distress. Before discussing treatment, a clinician should assess other possible contributors, including health conditions, medications, emotional well-being, and relationship factors.
A testosterone blood result alone cannot diagnose HSDD or show that treatment is appropriate. Testosterone levels are naturally low in women, and measurements at these concentrations can be difficult to interpret. Diagnosis depends on the person’s experience and a clinical assessment, not a laboratory number in isolation. The American Family Physician review of testosterone therapy describes evidence for use in postmenopausal women with HSDD, while noting that blood levels do not establish the diagnosis.
For some women with HSDD, treatment may improve sexual desire and related aspects of sexual function, but benefits are not guaranteed. Evidence does not support prescribing testosterone to address fatigue, low mood, or brain fog, or to prevent disease. A clinician can help weigh this limited potential benefit against possible effects such as acne, unwanted hair growth, voice changes, or changes in blood lipids.
There is no FDA-approved testosterone product specifically for women in the United States, so prescribing is off-label. That makes an informed discussion especially important: patients and clinicians can review the reason for treatment, expected benefits and uncertainties, possible side effects, and how response and safety would be monitored. For a broader discussion of clinician-directed use, see when testosterone may be considered.
Potential Benefits and Important Uncertainties
For some postmenopausal women with persistent, distressing low sexual desire diagnosed as hypoactive sexual desire disorder (HSDD), carefully monitored, low-dose testosterone may improve desire and sexual satisfaction. Evidence supports this specific use, not testosterone as a general treatment for aging or low energy. The American Family Physician review of testosterone therapy describes potential sexual-function benefits while noting that evidence for other outcomes is limited.
Improvements in fatigue, mood, concentration, muscle or bone health, and general well-being should not be assumed. These concerns may have other causes, so a clinician can help assess them before treatment is considered. At harmony.care, an individualized evaluation can place symptoms and hormone findings in the context of a woman’s broader health.
Possible side effects include acne or oilier skin, increased facial or body hair, and scalp hair thinning or loss. Higher-than-physiologic testosterone levels may cause voice deepening or clitoral enlargement, changes that can be difficult to reverse. Dosing and follow-up matter: the Mayo Clinic guidance on masculinizing hormone therapy notes that some testosterone-related physical changes may persist after treatment stops. That guidance concerns masculinizing therapy, so individual care for women requires its own clinical judgment.
Long-term effects on cardiovascular health and breast-cancer risk remain uncertain, and safety evidence for women is limited. In the United States, no testosterone product is FDA-approved specifically for women, so treatment is prescribed off-label. Before starting, discuss your symptoms, possible alternative explanations, medical history, and preferences with a qualified clinician. Agree on follow-up to review whether the intended benefit occurs, check for side effects, and monitor testosterone levels.
Recognizing Possible Side Effects
Testosterone can cause androgen-related changes such as acne, oilier skin, and increased facial or body hair. Some women may also notice thinning or loss of scalp hair. These effects vary from person to person, and clinical guidance on testosterone therapy in women identifies unwanted hair growth and acne among possible adverse effects.
Voice deepening and clitoral enlargement are less common concerns, but they deserve particular attention because they may be difficult to reverse. The likelihood of side effects depends in part on dose and blood levels. A clinician can review symptoms and test results to assess whether levels are within an appropriate range; do not change the dose on your own.
Report new or troubling changes to the prescribing clinician so the treatment plan can be reassessed. For women, testosterone products are not FDA-approved in the United States, and evidence about long-term safety remains limited. The American Family Physician review describes acne, excess hair growth, voice changes, and lipid changes as potential concerns, while noting that evidence beyond 24 months is lacking. Discuss these uncertainties before treatment, alongside the expected benefits and monitoring plan.
For a broader look at androgen-related changes, see possible side effects of testosterone therapy.
Choosing a Physiologic Dose
How is an appropriate testosterone dose determined for women? The decision starts with a clinician’s assessment of symptoms, health history, treatment goals, and whether the intended use is supported by evidence. Current guidance focuses on postmenopausal women with persistent, distressing low sexual desire diagnosed as hypoactive sexual desire disorder (HSDD), rather than using testosterone for general energy, mood, or aging concerns. Testosterone therapy guidance for women describes this limited clinical use.
A blood test cannot diagnose HSDD or determine the right dose. A baseline total testosterone measurement can help identify an unusually high level before treatment; follow-up testing helps prevent levels from rising above the physiologic range. Testing should be interpreted alongside clinical response and possible side effects, not used to chase an arbitrary testosterone target.
When treatment is appropriate, the clinical guidance describes low-dose transdermal testosterone, often beginning at about one-tenth of a typical male dose and adjusted to keep levels within the normal premenopausal female range. Reliable testing matters, since assays may be less accurate at the low concentrations typical in women. The International Society for the Study of Women’s Sexual Health recommendations support individualized care and monitoring rather than dose selection based on symptoms alone.
There is no FDA-approved testosterone product specifically for women in the United States. Compounded products, injections, pellets, and oral formulations are generally discouraged in the supplied guidance because their dosing and safety are less predictable. A clinician can review available options, monitor levels and response, and reduce or stop treatment if levels exceed the physiologic range or unwanted effects develop. For a broader discussion of dose selection and clinical guidance, see the related article.
Follow-Up and Laboratory Monitoring
Monitoring helps a clinician assess whether treatment is meeting its intended goal and whether the dose needs to change. A baseline total testosterone test provides a point of comparison, but it does not diagnose low sexual desire or, by itself, show that therapy is appropriate. For women with low desire, treatment decisions depend on a clinical assessment, not a target blood result alone.
After treatment begins, or after a dose change, a clinician may check total testosterone to help avoid levels above the normal premenopausal female range. Testing may be repeated periodically once the dose is stable. The American Family Physician review describes testosterone use in women for hypoactive sexual desire disorder and notes that evidence on longer-term safety remains limited.
Follow-up should also cover how the person feels and whether the targeted symptoms are improving. The clinician can ask about acne, increased facial or body hair, scalp hair thinning, and voice changes, which may signal excess androgen exposure. Any new or worsening changes are worth discussing promptly rather than adjusting the dose independently.
The schedule and decisions should reflect each person’s response, health history, and preferences. Discussing benefits alongside side effects can help determine whether continuing treatment remains reasonable, especially given the limits of long-term safety evidence. For broader context on testing as a reference point, see follow-up and laboratory monitoring.
Setting Expectations and Reviewing Progress
Before treatment begins, a clinician should review your symptoms, medical history, and goals, then discuss whether testosterone is appropriate for your situation. For women, its use is generally considered for persistent, distressing low sexual desire associated with hypoactive sexual desire disorder (HSDD), not as a general treatment for low energy or aging. Clinical guidance describes this as an off-label use in the United States, since no testosterone product is approved specifically for women.
What should women expect when starting testosterone therapy, and how soon might they notice changes? Some women with HSDD experience improved desire and sexual satisfaction, but benefits for energy, mood, cognition, or other concerns are not consistently supported. A clinician can help set goals that reflect the reason for treatment and your priorities.
Changes in desire may take several weeks to begin, and response can take a few months to assess. Timing and results vary, so agree in advance on when to review progress and what would count as a meaningful benefit. Individualized care, as described in harmony.care’s guidance on men’s hormone therapy, also emphasizes reviewing goals and symptoms rather than relying on a lab result alone.
Ask your clinician what trial period is appropriate and when lack of improvement would prompt a change or stopping treatment. Follow-up should also consider side effects and whether hormone levels remain within the premenopausal female range. Do not change the dose or stop treatment without discussing the plan with your clinician.
Stopping or Reconsidering Treatment
Can women stop testosterone therapy after starting it? Yes. Tapering is not usually required, but discuss the timing with your prescribing clinician before making a change. A follow-up can review the original treatment goal, the benefit you have noticed, any side effects, and whether another approach may better fit your needs.
If treatment was prescribed for distressing low sexual desire, symptoms may return after stopping if testosterone had been helping. Individual experiences vary, so a change in desire does not by itself determine whether treatment should be resumed.
Your clinician can help weigh these factors alongside your preferences and overall health. Follow-up may include reviewing symptoms and checking hormone levels when appropriate. For broader context on forms, dosing, and what to expect, see the related guide.
Supporting Well-Being Beyond Hormones
Can lifestyle changes or other approaches support healthy testosterone levels in women? Regular physical activity, restorative sleep, stress management, and balanced nutrition can support overall metabolic and hormonal health. Evidence that these habits specifically raise testosterone in women is limited, so they are best viewed as foundations for well-being rather than hormone treatments. Lifestyle support for broader health can complement, not replace, individualized medical care.
Chronic illness, medication effects, and substantial changes in weight may also be relevant when symptoms arise. A clinician can review these factors alongside medical history and symptoms; a low testosterone result alone does not establish a hormone deficiency in women, and tests can be difficult to interpret at the low concentrations typical in women.
When low sexual desire is persistent and distressing, an assessment should consider physical health, emotional well-being, medication effects, and relationship factors rather than assuming hormones are the cause. The American Family Physician review describes testosterone as a possible option only for selected postmenopausal women with hypoactive sexual desire disorder, not as treatment for general wellness. A personalized, evidence-based assessment is central to the women’s health care offered by harmony.care.
Testosterone is not a general wellness treatment. For eligible postmenopausal women, its use should be considered with a qualified clinician who can discuss the evidence, alternatives, and appropriate monitoring.
An Individualized Decision
Choosing testosterone therapy depends on the symptoms being addressed, personal goals, health history, and how well the evidence applies to that situation. For women, evidence supports considering testosterone for a specific concern, such as diagnosed hypoactive sexual desire disorder, rather than as a general treatment for energy, mood, or wellness. The American Family Physician review also notes that benefits and safety evidence for women remains limited.
A conversation with a qualified clinician can cover likely benefits and uncertainties, available formulations, dose, monitoring, and when to reassess whether treatment is helping. At harmony.care, hormone therapy is framed within individualized, evidence-based care, with attention to the broader context of a person's health and goals.
Testosterone is not a universal answer to concerns about well-being. A thoughtful decision weighs potential benefits against possible harms and considers other explanations and approaches, so the plan fits the person rather than relying on a one-size-fits-all expectation.
